Drugmaker AstraZeneca on Wednesday said that its experimental breast cancer treatment improved patient survival without the ...

The drug candidate improved progression-free survival in patients, it said.

The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer ...

The global breast cancer drugs market size was valued at USD 34.25 billion in 2024 and is projected to reach from USD 37.30 ...

Pharmaceuticals major AstraZeneca said on Wednesday that its experimental treatment, camizestrant, improved survival in ...

The partners are pushing to expand Enhertu’s list of indications beyond its standing uses in breast, lung and gastric cancers ...

Aliya Omer, VP, US franchise head, breast cancer, AstraZeneca, discusses how results of the trial compare with other treatments for gBRCAm HER2-negative high-risk early breast cancer.

AstraZeneca has reported positive outcomes from a planned interim analysis of the double-blind Phase III SERENA-6 trial of ...

AstraZeneca has advanced its push to make camizestrant a blockbuster, reporting a phase 3 win for the oral SERD at an interim ...

The Phase III SERENA-6 trial is the first global trial to use a circulating tumor DNA-guided approach to detect endocrine ...

Bank of America analysts estimate a peak sales potential of $6 billion for camizestrant across the SERENA-6 and SERENA-4 ...

Cambridge: AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been recommended for approval in the ...